HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
HER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3 upon inhibition of the HER family with the pan-HER...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0285251 |
| _version_ | 1797805665864908800 |
|---|---|
| author | Samar M Alanazi Wasim Feroz Rosalin Mishra Mary Kate Kilroy Hima Patel Long Yuan Sarah J Storr Joan T Garrett |
| author_facet | Samar M Alanazi Wasim Feroz Rosalin Mishra Mary Kate Kilroy Hima Patel Long Yuan Sarah J Storr Joan T Garrett |
| author_sort | Samar M Alanazi |
| collection | DOAJ |
| description | HER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3 upon inhibition of the HER family with the pan-HER inhibitor neratinib in HER2+ breast cancer cells. Immunoprecipitation of HER3 followed by mass spectrometry experiments found non-muscle myosin IIA (NMIIA) increased upon neratinib treatment relative to vehicle DMSO treatment. MYH9 is the gene that encodes for the heavy chain of NMIIA. Breast cancer patients with high MYH9 were significantly associated with a shorter disease specific survival compared to patients with low MYH9 expression from the METABRIC cohort of patients. In addition, high MYH9 expression was associated with HER2+ tumors from this cohort. Immunoblots of whole cell lysates of BT474 and MDA-MB-453 HER2+ breast cancer cells demonstrated elevated HER3 and NMIIA protein levels upon neratinib treatment for 24 hours. To examine the role of NMIIA in HER2+ breast cancer, we modulated NMIIA levels in BT474 and MDA-MB-453 cells using doxycycline inducible shRNA targeting MYH9. MYH9 knockdown reduces HER3 protein levels and concomitant reduction in downstream P-Akt. In addition, loss of MYH9 suppresses cell growth, proliferation, migration, and invasion. Our data reveals that NMIIA regulates HER3 and loss of NMIIA reduces HER2+ breast cancer growth. |
| first_indexed | 2024-03-13T05:55:29Z |
| format | Article |
| id | doaj.art-005fb3312dc84d4f917dde93496d688e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-13T05:55:29Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-005fb3312dc84d4f917dde93496d688e2023-06-13T05:31:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01185e028525110.1371/journal.pone.0285251HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.Samar M AlanaziWasim FerozRosalin MishraMary Kate KilroyHima PatelLong YuanSarah J StorrJoan T GarrettHER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3 upon inhibition of the HER family with the pan-HER inhibitor neratinib in HER2+ breast cancer cells. Immunoprecipitation of HER3 followed by mass spectrometry experiments found non-muscle myosin IIA (NMIIA) increased upon neratinib treatment relative to vehicle DMSO treatment. MYH9 is the gene that encodes for the heavy chain of NMIIA. Breast cancer patients with high MYH9 were significantly associated with a shorter disease specific survival compared to patients with low MYH9 expression from the METABRIC cohort of patients. In addition, high MYH9 expression was associated with HER2+ tumors from this cohort. Immunoblots of whole cell lysates of BT474 and MDA-MB-453 HER2+ breast cancer cells demonstrated elevated HER3 and NMIIA protein levels upon neratinib treatment for 24 hours. To examine the role of NMIIA in HER2+ breast cancer, we modulated NMIIA levels in BT474 and MDA-MB-453 cells using doxycycline inducible shRNA targeting MYH9. MYH9 knockdown reduces HER3 protein levels and concomitant reduction in downstream P-Akt. In addition, loss of MYH9 suppresses cell growth, proliferation, migration, and invasion. Our data reveals that NMIIA regulates HER3 and loss of NMIIA reduces HER2+ breast cancer growth.https://doi.org/10.1371/journal.pone.0285251 |
| spellingShingle | Samar M Alanazi Wasim Feroz Rosalin Mishra Mary Kate Kilroy Hima Patel Long Yuan Sarah J Storr Joan T Garrett HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PLoS ONE |
| title | HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. |
| title_full | HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. |
| title_fullStr | HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. |
| title_full_unstemmed | HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. |
| title_short | HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. |
| title_sort | her2 inhibition increases non muscle myosin iia to promote tumorigenesis in her2 breast cancers |
| url | https://doi.org/10.1371/journal.pone.0285251 |
| work_keys_str_mv | AT samarmalanazi her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT wasimferoz her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT rosalinmishra her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT marykatekilroy her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT himapatel her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT longyuan her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT sarahjstorr her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers AT joantgarrett her2inhibitionincreasesnonmusclemyosiniiatopromotetumorigenesisinher2breastcancers |